Associated Genetic Biomarkers
NCI Definition: A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood. Sezary syndrome is an aggressive disease. (WHO, 2001) 
There are 17 clinical trials for sezary syndrome, of which 16 are open and 1 is completed or closed. Of the trials that contain sezary syndrome as an inclusion criterion, 8 are phase 1 (7 open), 3 are phase 1/phase 2 (3 open), and 6 are phase 2 (6 open).
ALK is the most frequent gene inclusion criterion for sezary syndrome clinical trials .
Pembrolizumab, brentuximab vedotin, and mogamulizumab are the most common interventions in sezary syndrome clinical trials.
Significant Genes in Sezary Syndrome
ALK is an inclusion eligibility criterion in 1 clinical trial for sezary syndrome, of which 1 is open and 0 are closed. Of the trial that contains ALK status and sezary syndrome as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.